Axion BioSystems introduces Lumos™, a 48-well light delivery device allowing you to incorporate cutting-edge optical assay techniques such as optogenetics, into your in vitro research. Lumos delivers user-specified intensity and duration of light from up to four wavelengths simultaneously for ultimate assay flexibility.
Optogenetics is a research technique that uses genetic targeting to express light-sensitive ion channels (opsins) in specific cell populations. When stimulated with the opsin-specific activation wavelength, those ion channels are activated and intrinsic cellular activity will be stimulated or suppressed.
Emerging optical stimulation techniques such as optogenetics (Nature Method of the Year, 2010) allow an unprecedented ability to selectively control cellular function. This newfound ability to precisely manipulate in vitro preparations has the potential to transform assays in diverse fields including disease modeling, stem cell therapeutics, and molecular biology. However the wide-spread implementation of these powerful techniques has been limited to date by rudimentary control or low-throughput with cumbersome custom-built setups.
A first-of-its-kind on the market, Lumos revolutionizes in vitro optical approaches by providing 48 concurrent wells of stimulation and the ability to simultaneously use up to four different wavelengths of light per well at user-specified intensity and duration.
- Independent, simultaneous control of light delivery to a standard SLAS-compliant 48-well plate
- Four individually-controllable LEDs per well spanning the visible light spectrum
- Generation of optical stimulation patterns with microsecond precision stimulation
- Uniform illumination across the entire well
- Intuitive stimulation programming in AxIS control software
- Optional pairing with the Maestro MEA system to precisely control cellular activity from the top while simultaneously recording real-time functional responses on the MEA plate
We’ve provided a comprehensive optical stimulation tool with the throughput and flexibility that is the first for any in vitro application. Whether using Lumos in conjunction with the Maestro MEA platform for neural or cardiac applicatinos, or independently to control iPSC differentiation, gene expression or control of other cellular functions, we’ve created hardware, software, and analysis tools to make Lumos a must-have tool for all research arenas.
See how Lumos’ high-throughput, in vitro optogenetic approach is making an immediate difference in advancing a range of applications including cell biology, biochemistry, and molecular biology approaches.
|Document type||Title||Authors||Requires sign in|
|Product Brochure||AXION MEA PLATES 768 electrodes: Industry-leading electrode count at throughput you need||Axion BioSystems|
|Product Brochure||LUMOS™ 48-well optogenetic stimulation for the Maestro™ MEA platform||Axion BioSystems|
|News and Events||SfN2016 poster list||Axion BioSystems|
|Product Brochure||Lumos: 48-well optical stimulation device||Axion BioSystems|
|News and Events||Axion BioSystems Travel Award||Axion BioSystems|
|News and Events||SOT2017 Poster & Presentations list||Axion BioSystems|
|Application Document||Lumos MEA 48 - Product flyer||Axion BioSystems, Axiogenesis|
|Product Brochure||MEA Plates - Brochure||Axion BioSystems|
|Technical Datasheet||Lumos MEA 48 - Datasheet||Axion BioSystems||✔|
||The CiPA Microelectrode Array Assay with hSC-Derived Cardiomyocytes: Current Protocol, Future Potential||Millard DC, Clements M, Ross JD.||Stem Cell-Derived Models in Toxicology||Nov 2016|
||Optogenetic stimulation of multiwell MEA plates for neural and cardiac applications||Clements IP, Millard DC, Nicolini AM, Preyer AJ, Grier R, Heckerling A, Blum RA, Tyler P, McSweeney KM, Lu YF, Hall D, Ross JD.||Proc. SPIE 9690||Mar 2016|
||Lumos: A multiwell optical stimulation device for precise control of cell activity||Clements IP, Clements M, Millard DC, Nicolini AM, Arrowood CA, Chvatal SA, Ross JD.||SLAS||2017|
||Quantification of seizurogenic activity with multiwell microelectrode array technology for proconvulsant risk assessment and disease-in-a-dish epilepsy models||Millard DC, Hayes HB, Nicolini AM, Arrowood CA, Ross JD.||Society for Neuroscience||2016|
||LumosTM: a multiwell optogenetic stimulation device for the precise control of in vitro cellular network activity||Millard DC, Clements IP, Nicolini AM, Arrowood CA, Parrish C, Ross JD.||SLAS||2016|
||Simultaneous multiwell optogenetic stimulation and microelectrode array recording for disease modeling and toxicological assays||Clements IP, Millard DC, Hayes HB, Nicolini AM, Arrowood CA, Ross JD.||Society for Neuroscience||2016|
||Quantification of Seizurogenic Activity with Multiwell Microelectrode Array Technology for Proconvulsant Risk Assessment and Disease-in-a-Dish Epilepsy Models||Millard DC, Hayes HB, Nicolini AM, Arrowood CA, Ross JD.||Society for Neuroscience||2016|
||Multiwell optogenetic stimulation for MEA-based disease modeling and drug discovery||Clements IP, Millard DC, Nicolini AM, Preyer AJ, Blum RA, Ross J, Qin N, Rubin R, Mekhoubad S, Cooper O, Chiao E.||Society for Neuroscience||2015|
||Stimulation-based endpoints for assessing seizurogenic activity with multiwell microelectrode array technology||Millard DC, Nicolini AM, Arrowood CA, Ross JD.||Society for Neuroscience||2015|
||Optically integrated multiwell microelectrode arrays: High-throughput disease modeling and drug discovery with optogenetics||Clements IP, Millard DC, Nicolini AM, Brock MW, Preyer AJ, Ross JD.||Society for Neuroscience||2014|